Literature DB >> 7860622

Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas.

J Rehbock1, P Buchinger, A Hermann, C Figueroa.   

Abstract

Various proteases have been shown to be present in malignant breast tissue. Although the question of the involvement of tissue kallikrein, a serine protease, in the pathophysiology of tumours has been raised, the presence of this enzyme in human breast carcinoma has so far not been examined. In the present study, both neoplastic and normal human breast are scanned by immunocytochemistry for the presence and cellular localization of tissue kallikrein. In the healthy breast, tissue kallikrein was observed as a deposit of immunoreactive material that localized in the apical portion of duct cells. In the malignant breast tumours surveyed, the enzyme was observed only in ductal carcinomas, whereas lobular carcinomas were devoid of immunostaining. In ductal carcinomas, the immunoreactivity for tissue kallikrein appeared to be associated with gradations of malignancy, being absent in dedifferentiated tumours. The presence of tissue kallikrein in malignant breast tumours poses the question of the role of this enzyme in malignant breast tissue. The enzyme may participate within the tissue either in proteolytic processes (it has been shown to activate procollagenase) or by enhancing vascularity or mitogenicity by the generation of kinins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7860622     DOI: 10.1007/bf01202732

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  19 in total

Review 1.  Bioregulation of kinins: kallikreins, kininogens, and kininases.

Authors:  K D Bhoola; C D Figueroa; K Worthy
Journal:  Pharmacol Rev       Date:  1992-03       Impact factor: 25.468

2.  Prolactin proteolysis by glandular kallikrein: in vitro reaction requirements and cleavage sites, and detection of processed prolactin in vivo.

Authors:  C A Powers; M A Hatala
Journal:  Endocrinology       Date:  1990-10       Impact factor: 4.736

3.  Activation of the 92 kDa type IV collagenase by tissue kallikrein.

Authors:  S Desrivières; H Lu; N Peyri; C Soria; Y Legrand; S Ménashi
Journal:  J Cell Physiol       Date:  1993-12       Impact factor: 6.384

4.  Kallikrein activation of a high molecular weight atrial peptide.

Authors:  M G Currie; D M Geller; J Chao; H S Margolius; P Needleman
Journal:  Biochem Biophys Res Commun       Date:  1984-04-30       Impact factor: 3.575

5.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

6.  Increased proteinase expression during tumor progression of cell lines down-modulated for TIMP levels: a new transformation paradigm? [corrected].

Authors:  R Khokha; P Waterhouse; P Lala; M Zimmer; D T Denhardt; R Khokka
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

7.  Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.

Authors:  F M Chybowski; J J Keller; E J Bergstralh; J E Oesterling
Journal:  J Urol       Date:  1991-02       Impact factor: 7.450

8.  Development and characterization of a radioimmunoassay to measure human tissue kallikrein in biological fluids.

Authors:  A F Bagshaw; K D Bhoola; M J Lemon; J T Whicher
Journal:  J Endocrinol       Date:  1984-05       Impact factor: 4.286

9.  Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis is increased by expression of a mutant ras oncogene.

Authors:  R A Roberts; W J Gullick
Journal:  J Cell Sci       Date:  1989-11       Impact factor: 5.285

10.  Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue.

Authors:  Y Matsumura; M Kimura; T Yamamoto; H Maeda
Journal:  Jpn J Cancer Res       Date:  1988-12
View more
  3 in total

1.  A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness.

Authors:  W C Wolf; D M Evans; L Chao; J Chao
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma.

Authors:  Z Dlamini; K D Bhoola
Journal:  J Clin Pathol       Date:  2005-09       Impact factor: 3.411

3.  Targeting intracellular B2 receptors using novel cell-penetrating antagonists to arrest growth and induce apoptosis in human triple-negative breast cancer.

Authors:  Céléna Dubuc; Martin Savard; Veronica Bovenzi; Andrée Lessard; Audrey Fortier; Jérôme Côté; Witold Neugebauer; Flavio Rizzolio; Sameh Geha; Antonio Giordano; Sylvain Chemtob; Fernand Gobeil
Journal:  Oncotarget       Date:  2018-01-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.